Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:antigen |
gptkb:CD19
|
| gptkbp:clinicalTrialPhase |
Phase 1/2a
|
| gptkbp:developedBy |
Precision BioSciences
|
| gptkbp:firstClinicalTrial |
2018
|
| gptkbp:geneEditingTechnology |
ARCUS
|
| gptkbp:hasCompany |
gptkb:Durham,_North_Carolina,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
PBCAR0191
|
| gptkbp:indication |
relapsed or refractory B-cell malignancies
|
| gptkbp:manufacturer |
allogeneic
|
| gptkbp:mechanismOfAction |
redirects T cells to target and kill CD19-expressing cancer cells
|
| gptkbp:regulates |
Investigational
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:source |
healthy donor T cells
|
| gptkbp:trialIdentifier |
NCT03666000
|
| gptkbp:bfsParent |
gptkb:Precision_Biosciences
|
| gptkbp:bfsLayer |
7
|